- Sanjiv (Sam) Gambhir, MD, PhD
- James D. Marks, MD
- Peter Senter, PhD
- Dane Wittrup, PhD
- Michael R. Zalutsky, PhD
Dr. Gambhir is the Virginia and D.K. Ludwig Professor in Cancer Research, Chairman of the Department of Radiology at Stanford University School of Medicine, and a professor by courtesy in the departments of Bioengineering and Materials Science and Engineering at Stanford University. He serves as the Director of the Molecular Imaging Program at Stanford (MIPS) and Canary Center at Stanford for Cancer Early Detection. Internationally regarded as a leader in the field of molecular imaging, Dr. Gambhir’s research and clinical development has transformed the field of nuclear medicine, PET and optical imaging as represented in over 250 peer reviewed publications. Dr. Gambhir has been recognized by the Society of Nuclear Medicine through several prestigious scientific awards, including the Aebersold Award and the Hounsfield Medal Award.
Dr. Marks is a Professor of Anesthesia at the University of California, San Francisco (UCSF). He is highly recognized as a pioneer in the field of antibody engineering, especially the use of antibody gene diversity libraries and display technologies to generate human therapeutic antibodies. He also has extensive experience in the biotechnology industry, having co-founded Hermes Biosciences., an early stage biotechnology company focused on the development of antibody targeted immunoliposomes for cancer therapy that was acquired by Merrimack Pharmaceuticals in 2009. Dr. Marks serves on several biopharmaceutical scientific advisory boards, has more than 180 relevant publications in the field and is an inventor on more than 100 issued or pending patents.
Dr. Senter is the Vice President of Chemistry at Seattle Genetics. His research surrounds targeted cancer therapy, with emphasis on monoclonal antibody-based delivery systems. The work from his laboratory provided the technology basis for brentuximab vedotin, a drug recently approved drug for the treatment of relapsed Hodgkin lymphoma and anaplastic large cell lymphoma. Other areas of research include drug and prodrug design and synthesis, and novel fusion proteins for selective drug activation. Prior to joining Seattle Genetics in 1998, Dr. Senter held positions at Bristol-Myers Squibb Pharmaceutical Research Institute, Cytokine Networks, and the Dana-Farber Cancer Institute. He serves as Senior Editor of Bioconjugate Chemistry, and as Affiliate Professor of Bioengineering at the University of Washington. Dr. Senter received a PhD in Chemistry from the University of Illinois and an AB in Biochemistry from the University of California, Berkeley.
Dr. Wittrup is the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT and Associate Director of MIT’s Koch Institute. In 2012, he was elected to the National Academy of Engineering. He was also elected a Fellow of the American Association for the Advancement of Science in 2011. Dr. Wittrup is co-founder and acting Chief Scientific Officer at Adimab and is a fellow of the American Institute of Biomedical Engineers. He has also served as the J. W. Westwater Professor of Chemical Engineering, Biophysics, and Bioengineering at the University of Illinois at Urbana-Champaign. He previously worked as a postdoctoral research associate in Amgen’s Yeast Molecular Biology Group. He holds a PhD and MS in Chemical Engineering from the California Institute of Technology and a BS in Chemical Engineering from the University of New Mexico.
Dr. Zalutsky is the Jonathan Spicehandler, MD, Professor of Neuro-Oncology Research and a Professor in the Departments of Radiology, Radiation Oncology and Biomedical Engineering at Duke University. The author of more than 325 scientific publications, his primary research interest is radiochemistry applied to cancer imaging and therapy. Dr. Zalutsky’s honors and awards include the Berson-Yalow Award and the Aebersold Award from the Society of Nuclear Medicine. He also received a 10-year MERIT Award from the National Cancer Institute for his work in targeted radionuclide therapy.